Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) have earned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $5.89.

Several research analysts recently issued reports on ANTH shares. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $1.75 target price (down from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th.

Institutional investors have recently modified their holdings of the business. Wedbush Securities Inc. increased its stake in shares of Anthera Pharmaceuticals by 75.8% during the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 31,800 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Anthera Pharmaceuticals by 1,376.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 335,595 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of Anthera Pharmaceuticals by 9.9% during the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 33,901 shares in the last quarter. 16.24% of the stock is owned by institutional investors.

Anthera Pharmaceuticals (ANTH) traded up $0.09 during midday trading on Friday, reaching $1.60. 268,551 shares of the company traded hands, compared to its average volume of 341,707. Anthera Pharmaceuticals has a 52-week low of $1.20 and a 52-week high of $17.04.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.32. During the same quarter in the previous year, the firm earned ($4.85) EPS. analysts predict that Anthera Pharmaceuticals will post -3.14 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Anthera Pharmaceuticals, Inc. (ANTH) Given Average Rating of “Hold” by Brokerages” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/08/anthera-pharmaceuticals-inc-anth-given-average-rating-of-hold-by-brokerages.html.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.